Drug Candidates for the Treatment of Gynecologic Cancer
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: closed (30 June 2023) | Viewed by 275
Special Issue Editors
Interests: agricultural science; functional food; reproductive endocrine
Special Issues, Collections and Topics in MDPI journals
Interests: genomics; proteomics; bioinformatics; cell and molecular biology; cancer biology
Special Issue Information
Dear Colleagues,
Gynecological cancers, including breast cancer, cervical cancer, ovarian cancer and endometrial cancer, have an increasing prevalence and mortality worldwide. Although cancer mortality can be controlled through early detection through screening and various chemoradiotherapy and surgery, most women who have cancer suffer from cancer treatment and side effects. Different sensitivities to drugs also lead to different degrees of recurrence rates. Therefore, novel agents are urgently needed to improve the therapeutic effect of cancer.This Special Issue focuses on more targeted therapies for gynecologic cancer and explores the mechanism of the drugs or compounds involved in treating gynecological tumors. For those in the research field, it is important to propose new and updated mechanisms of cancer progression, which may lead to the identification of new drug targets and new therapies. Regarding the direction of research, we suggest involving novel chemotherapeutic drugs that are undergoing clinical trials or new drugs in the preclinical stage and describing their possible mechanisms against gynecological tumors.
Pharmaceuticals invites reviews and original articles contributions to the latest advances and pathogenesis in clinical gynecological cancer treatment and provides potential therapeutics as drug candidates. We welcome papers reviewing the latest research on this topic in the present Special Issue. We look forward to your contribution.
Prof. Dr. Shih-Min Hsia
Dr. Tsui-Chin Huang
Dr. Hsin-Yuan Chen
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- gynecologic cancer
- metastasis
- molecular mechanism
- chemotherapy
- targeted therapy
- clinical trials
